Deciphering the divergent roles of progestogens in breast cancer

Nature Reviews Cancer

Volumn 17, Issue 1, 2017, Pages 54-64

  Carroll, Jason S ^a   Hickey, Theresa E ^b   Tarulli, Gerard A ^b   Williams, Michael ^c   Tilley, Wayne D ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

BREAST; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER CELL; CANCER RISK; HORMONE RESPONSE; HUMAN; INTRACELLULAR SIGNALING; MEDICAL TERMINOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM; PATHOPHYSIOLOGY;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; PROGESTINS; RECEPTORS, PROGESTERONE;

EID: 84996938097     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.116     Document Type: Review

References (171)

1. Stierer, M., et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann. Surg. 218, 13-21 (1993
2. Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58, 685-704 (2006
3. Musgrove, E. A., & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009
4. Toy, W., et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013
5. Robinson, D. R., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013
6. Merenbakh-Lamin, K., et al. D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73, 6856-6864 (2013
7. Pannuti, F., et al. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur. J. Cancer 15, 593-601 (1979
8. Alexieva-Figusch, J., et al. Progestin therapy in advanced breast cancer: megestrol acetate-An evaluation of 160 treated cases. Cancer 46, 2369-2372 (1980
9. Izuo, M., Iino, Y., & Endo, K. Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies. Breast Cancer Res. Treat. 1, 125-130 (1981
10. Ingle, J. N., et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am. J. Clin. Oncol. 5, 155-160 (1982
11. Mattsson, W. Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res. Treat. 3, 231-235 (1983
12. Morgan, L. R. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin. Oncol. 12, 43-47 (1985
13. Espie, M. Megestrol acetate in advanced breast carcinoma. Oncology 51 (Suppl. 1), 8-12 (1994
14. Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J. Clin. Oncol. 13, 1572-1577 (1995
15. Muss, H. B., et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5 year analysis-A phase III trial of the Piedmont Oncology Association. J. Clin. Oncol. 6, 1098-1106 (1988
16. Robertson, J. F., et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur. J. Cancer Clin. Oncol. 25, 469-475 (1989
17. Abrams, J., et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J. Clin. Oncol. 17, 64-73 (1999
18. Bines, J., et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann. Oncol. 25, 831-836 (2014
19. Beral, V., et al. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427 (2003
20. Chlebowski, R. T., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 289, 3243-3253 (2003
21. Rossouw, J. E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002
22. Wu, J., Richer, J., Horwitz, KB., & Hyder, S. M. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 64, 2238-2244 (2004
23. Liang, Y., Besch-Williford, C., Brekken, R. A., & Hyder, S. M. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res. 67, 9929-9936 (2007
24. Faivre, E. J., & Lange, C. A. Progesterone receptors upregulate Wnt 1 to induce epidermal growth factor receptor transactivation and c Src-dependent sustained activation of Erk1/2 mitogen-Activated protein kinase in breast cancer cells. Mol. Cell. Biol. 27, 466-480 (2007
25. Lanari, C., et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr. Relat. Cancer 16, 333-350 (2009
26. Giulianelli, S., et al. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the Cyclin D1/MYC promoters. Cancer Res. 72, 2416-2427 (2012
27. Tanos, T., et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci. Transl Med. 5, 182ra155 (2013
28. Dressing, G. E., et al. Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol. Endocrinol. 28, 442-457 (2014
29. Carroll, J. S., & Brown, M. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 20, 1707-1714 (2006
30. Kininis, M., & Kraus, W. L. A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. Nucl. Recept. Signal. 6, e005 (2008
31. Peters, A. A., et al. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res. 69, 6131-6140 (2009
32. Arora, V. K., et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309-1322 (2013
33. Daniel, A. R., et al. Progesterone receptor B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1-And estrogen receptor-containing transcription complexes. Oncogene 34, 506-515 (2015
34. Isikbay, M., et al. Glucocorticoid receptor activity contributes to resistance to androgen-Targeted therapy in prostate cancer. Horm. Cancer 5, 72-89 (2014
35. Mohammed, H., et al. Progesterone receptor modulates ERα action in breast cancer. Nature 523, 313-317 (2015
36. Carreau, S., & Levallet, J. Testicular estrogens and male reproduction. News Physiol. Sci. 15, 195-198 (2000
37. Oettel, M., & Mukhopadhyay, A. K. Progesterone: the forgotten hormone in men? Aging Male 7, 236-257 (2004
38. Graham, J. D., & Clarke, C. L. Physiological action of progesterone in target tissues. Endocr. Rev. 18, 502-519 (1997
39. Edwards, D. P. Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 67, 335-376 (2005
40. Horwitz, K. B., & McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J. Biol. Chem. 253, 2223-2228 (1978
41. Pichon, M. F., Pallud, C., Brunet, M., & Milgrom, E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 40, 3357-3360 (1980
42. Ballare, C., et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c Src/Erk pathway in mammalian cells. Mol. Cell. Biol. 23, 1994-2008 (2003
43. Muscat, G. E., et al. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol. Endocrinol. 27, 350-365 (2013
44. Santagata, S., et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J. Clin. Invest. 124, 859-870 (2014
45. Horwitz, K. B., & McGuire, W. L. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189, 726-727 (1975
46. Viale, G., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 25, 3846-3852 (2007
47. Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr. Rev. 34, 171-208 (2013
48. Del Vecchio, R. P. The role of steroidogenic and nonsteroidogenic luteal cell interactions in regulating progesterone production. Semin. Reprod. Endocrinol. 15, 409-420 (1997
49. Chaumeil, J. C. Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find. Exp. Clin. Pharmacol. 20, 211-215 (1998
50. Hargrove, J. T., Maxson, W. S., & Wentz, A. C. Absorption of oral progesterone is influenced by vehicle and particle size. Am. J. Obstet. Gynecol. 161, 948-951 (1989
51. Lauritzen, C. Clinical use of oestrogens and progestogens. Maturitas 12, 199-214 (1990
52. Apgar, B. S., & Greenberg, G. Using progestins in clinical practice. Am. Fam. Physician 62, 1839-1846 (2000
53. Fournier, A., Berrino, F., & Clavel-Chapelon, F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107, 103-111 (2008
54. Chlebowski, R. T., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360, 573-587 (2009
55. Lyytinen, H. K., Dyba, T., Ylikorkala, O., & Pukkala, E. I. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int. J. Cancer 126, 483-489 (2010
56. Manson, J. E., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310, 1353-1368 (2013
57. Reeves, G. K., Beral, V., Green, J., Gathani, T., & Bull, D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-Analysis. Lancet Oncol. 7, 910-918 (2006
58. Dieci, M. V., Orvieto, E., Dominici, M., Conte, P., & Guarneri, V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist 19, 805-813 (2014
59. McCart Reed, A. E., Kutasovic, J. R., Lakhani, S. R., & Simpson, P. T. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res. 17, 12 (2015
60. Burger, H. G., MacLennan, A. H., Huang, K. E., & Castelo-Branco, C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 15, 281-287 (2012
61. Schernhammer, E. S., et al. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Res. 15, R46 (2013
62. Eliassen, A. H., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J. Natl Cancer Inst. 98, 1406-1415 (2006
63. Kaaks, R., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl Cancer Inst. 97, 755-765 (2005
64. Chang, K. J., Lee, T. T., Linares-Cruz, G., Fournier, S., & de Lignieres, B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil. Steril. 63, 785-791 (1995
65. Clavel-Chapelon, F., & Dormoy-Mortier, N. A validation study on status and age of natural menopause reported in the E3N cohort. Maturitas 29, 99-103 (1998
66. Fournier, A., Berrino, F., Riboli, E., Avenel, V., & Clavel-Chapelon, F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114, 448-454 (2005
67. Fournier, A., et al. Use of different postmenopausal hormone therapies and risk of histology-And hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 26, 1260-1268 (2008
68. de Lignieres, B., et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3, 175 women. Climacteric 5, 332-340 (2002
69. Espie, M., et al. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol. Endocrinol. 23, 391-397 (2007
70. Schneider, C., Jick, S. S., & Meier, C. R. Risk of gynecological cancers in users of estradiol/ dydrogesterone or other HRT preparations. Climacteric 12, 514-524 (2009
71. Cordina-Duverger, E., et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS ONE 8, e78016 (2013
72. Fournier, A., et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res. Treat. 145, 535-543 (2014
73. Lippman, M. E., et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J. Clin. Oncol. 19, 3111-3116 (2001
74. Asi, N., et al. Progesterone versus synthetic progestins and the risk of breast cancer: a systematic review and meta-Analysis. Syst. Rev. 5, 121 (2016
75. Foidart, J. M., Desreux, J., Pintiaux, A., & Gompel, A. Hormone therapy and breast cancer risk. Climacteric 10 (Suppl. 2), 54-61 (2007
76. L'Hermite, M., Simoncini, T., Fuller, S., & Genazzani, A. R. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 60, 185-201 (2008
77. Gadducci, A., Biglia, N., Cosio, S., Sismondi, P., & Genazzani, A. R. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol. Endocrinol. 25, 807-815 (2009
78. Mueck, A. O., Seeger, H., & Buhling, K. J. Use of dydrogesterone in hormone replacement therapy. Maturitas 65 (Suppl. 1), S51-S60 (2009
79. Wood, C. E., et al. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res. Treat. 101, 125-134 (2007
80. LaCroix, A. Z. Estrogen with and without progestin: benefits and risks of short-Term use. Am. J. Med. 118 (Suppl. 12B), 79-87 (2005
81. Bentel, J. M., et al. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol. Cell. Endocrinol. 154, 11-20 (1999
82. Ouatas, T., Halverson, D., & Steeg, P. S. Dexamethasone and medroxyprogesterone acetate elevate Nm23 H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin. Cancer Res. 9, 3763-3772 (2003
83. Birrell, S. N., Butler, L. M., Harris, J. M., Buchanan, G., & Tilley, W. D. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 21, 2285-2293 (2007
84. Bonomi, P., et al. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin. Oncol. 12, 48-54 (1985
85. Johnson, P. A., et al. Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat. Rep. 67, 717-720 (1983
86. Carpenter, J. T. in Endocrine Therapies in Breast and Prostate Cancer (ed. Osborne, C. K.) 147-156 (Kluwer, 1988
87. Sutherland, R. L., Hall, R. E., Pang, G. Y., Musgrove, E. A., & Clarke, C. L. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res. 48, 5084-5091 (1988
88. Poulin, R., Baker, D., Poirier, D., & Labrie, F. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR 75 1 human breast cancer cells. Breast Cancer Res. Treat. 13, 161-172 (1989
89. Ory, K., et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res. Treat. 68, 187-198 (2001
90. Ochnik, A. M., et al. Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause 21, 79-88 (2014
91. Gizard, F., et al. Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett. 579, 5535-5541 (2005
92. Kabos, P., et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res. Treat.135, 415-432 (2012
93. Vignon, F., Bardon, S., Chalbos, D., & Rochefort, H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J. Clin. Endocrinol. Metab. 56, 1124-1130 (1983
94. Stingl, J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm. Cancer 2, 85-90 (2011
95. Beleut, M., et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA 107, 2989-2994 (2010
96. Brisken, C., et al. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc. Natl Acad. Sci. USA 95, 5076-5081 (1998
97. Shoker, B. S., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am. J. Pathol. 155, 1811-1815 (1999
98. Russo, J., Ao, X., Grill, C., & Russo, I. H. Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53, 217-227 (1999
99. De Silva, D., Kunasegaran, K., Ghosh, S., & Pietersen, A. M. Transcriptome analysis of the hormone-sensing cells in mammary epithelial reveals dynamic changes in early pregnancy. BMC Dev. Biol. 15, 7 (2015
100. Virgo, B. B., & Bellward, G. D. Serum progesterone levels in the pregnant and postpartum laboratory mouse. Endocrinology 95, 1486-1490 (1974
101. Ewan, K. B., et al. Proliferation of estrogen receptor-α-positive mammary epithelial cells is restrained by transforming growth factor β1 in adult mice. Am. J. Pathol. 167, 409-417 (2005
102. Mastroianni, M., et al. Wnt signaling can substitute for estrogen to induce division of ERα-positive cells in a mouse mammary tumor model. Cancer Lett. 289, 23-31 (2010
103. Fridriksdottir, A. J., et al. Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. Nat. Commun. 6, 8786 (2015
104. Dontu, G., & Ince, T. A. Of mice and women: a comparative tissue biology perspective of breast stem cells and differentiation. J. Mammary Gland Biol. Neoplasia 20, 51-62 (2015
105. Schramek, D., Sigl, V., & Penninger, J. M. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol. Metab. 22, 188-194 (2011
106. Hiremath, M., Lydon, J. P., & Cowin, P. The pattern of β-catenin responsiveness within the mammary gland is regulated by progesterone receptor. Development 134, 3703-3712 (2007
107. Graham, J. D., et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150, 3318-3326 (2009
108. McManus, M. J., & Welsch, C. W. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 54, 1920-1927 (1984
109. Laidlaw, I. J., et al. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136, 164-171 (1995
110. Foidart, J. M., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil. Steril. 69, 963-969 (1998
111. Hilton, H. N., et al. Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget 5, 8651-8664 (2014
112. De Maeyer, L., et al. Does estrogen receptor negative/ progesterone receptor positive breast carcinoma exist? J. Clin. Oncol. 26, 335-336 (2008
113. Quong, J., et al. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res. Treat. 76, 221-236 (2002
114. Azim, H. A. Jr., et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 17, 24 (2015
115. Sanger, N., et al. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. Mol. Oncol. 8, 1196-1207 (2014
116. Blows, F. M., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 7, e1000279 (2010
117. Purdie, C. A., et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br. J. Cancer 110, 565-572 (2014
118. Welsh, A. W., et al. Cytoplasmic estrogen receptor in breast cancer. Clin. Cancer Res. 18, 118-126 (2012
119. Singhal, H., et al. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci. Adv. 2, e1501924 (2016
120. Zheng, Z. Y., Bay, B. H., Aw, S. E., & Lin, V. C. A novel antiestrogenic mechanism in progesterone receptor-Transfected breast cancer cells. J. Biol. Chem. 280, 17480-17487 (2005
121. Swarbrick, A., Lee, C. S., Sutherland, R. L., & Musgrove, E. A. Cooperation of p27Kip1 and p18INK4c in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20, 2581-2591 (2000
122. Musgrove, E. A., Swarbrick, A., Lee, C. S., Cornish, A. L., & Sutherland, R. L. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18, 1812-1825 (1998
123. Prall, O. W., Sarcevic, B., Musgrove, E. A., Watts, C. K., & Sutherland, R. L. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272, 10882-10894 (1997
124. Hagan, C. R., Daniel, A. R., Dressing, G. E., & Lange, C. A. Role of phosphorylation in progesterone receptor signaling and specificity. Mol. Cell. Endocrinol. 357, 43-49 (2012
125. Hagan, C. R., & Lange, C. A. Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med. 12, 32 (2014
126. Musgrove, E. A., Lee, C. S., & Sutherland, R. L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c fos, and c myc genes. Mol. Cell. Biol. 11, 5032-5043 (1991
127. Groshong, S. D., et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, 21 and p27Kip1. Mol. Endocrinol. 11, 1593-1607 (1997
128. Chalbos, D., & Rochefort, H. Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells. J. Biol. Chem. 259, 1231-1238 (1984
129. Hissom, J. R., & Moore, M. R. Progestin effects on growth in the human breast cancer cell line T-47D-possible therapeutic implications. Biochem. Biophys. Res. Commun. 145, 706-711 (1987
130. Graham, J. D., et al. Progesterone receptor A and B protein expression in human breast cancer. J. Steroid Biochem. Mol. Biol. 56, 93-98 (1996
131. Graham, J. D., et al. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol. Endocrinol. 19, 2713-2735 (2005
132. Sartorius, C. A., et al. New T47D breast cancer cell lines for the independent study of progesterone B-And A-receptors: only antiprogestin-occupied B receptors are switched to transcriptional agonists by cAMP. Cancer Res. 54, 3868-3877 (1994
133. Graham, M. L. 2nd et al. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 50, 6208-6217 (1990
134. Berkenstam, A., Glaumann, H., Martin, M., Gustafsson, J. A., & Norstedt, G. Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF 7 breast cancer cells. Mol. Endocrinol. 3, 22-28 (1989
135. Harvell, D. M., Richer, J. K., Allred, D. C., Sartorius, C. A., & Horwitz, K. B. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology 147, 700-713 (2006
136. Sartorius, C. A., Shen, T., & Horwitz, K. B. Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res. Treat. 79, 287-299 (2003
137. Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P., & Morales, A. R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5, 993 breast cancers. Am. J. Clin. Pathol. 123, 21-27 (2005
138. Hefti, M. M., et al. Estrogen receptor negative/ progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 15, R68 (2013
139. Cerliani, J. P., et al. Interaction between FGFR 2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 71, 3720-3731 (2011
140. Howlader, N., et al. SEER Cancer Statistics Review, 1975-2009 National Cancer Institute http://seer. cancer.gov/archive/csr/1975-2009-pops09/results- merged/sect-04-breast.pdf (2006
141. Howell, A., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005
142. BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766-776 (2009
143. Melmon, K. L., Morrelli, H. F., & Carruthers, S. G. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics (McGraw Hill Professional, 2000
144. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21, 1973-1979 (2003
145. Stendahl, M., et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin. Cancer Res. 12, 4614-4618 (2006
146. Jonat, W., et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 32A, 404-412 (1996
147. Buzdar, A. U., et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79, 730-739 (1997
148. Buzdar, A., et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19, 3357-3366 (2001
149. Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J. Clin. Oncol. 21, 602-606 (2003
150. Kligman, L., & Younus, J. Management of hot flashes in women with breast cancer. Curr. Oncol. 17, 81-86 (2010
151. Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M., & McCowan, C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br. J. Cancer 108, 1515-1524 (2013
152. Loprinzi, C. L., et al. Megestrol acetate for the prevention of hot flashes. N. Engl. J. Med. 331, 347-352 (1994
153. Hickey, T. E., Robinson, J. L., Carroll, J. S., & Tilley, W. D. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol. Endocrinol. 26, 1252-1267 (2012
154. Hua, S., Kittler, R., & White, K. P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259-1271 (2009
155. Ross-Innes, C. S., et al. Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancer. Genes Dev. 24, 171-182 (2010
156. Darro, F., et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU 486 anti-progestagen. Breast Cancer Res. Treat. 51, 39-55 (1998
157. Vilasco, M., et al. Glucocorticoid receptor and breast cancer. Breast Cancer Res. Treat. 130, 1-10 (2011
158. Miranda, T. B., et al. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 73, 5130-5139 (2013
159. De Amicis, F., et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res. Treat. 121, 1-11 (2010
160. Rechoum, Y., et al. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Res. Treat. 147, 473-485 (2014
161. Bardon, S., Vignon, F., Chalbos, D., & Rochefort, H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab. 60, 692-697 (1985
162. Horwitz, K. B. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. Endocrinology 116, 2236-2245 (1985
163. Musgrove, E. A., Lee, C. S., Cornish, A. L., Swarbrick, A., & Sutherland, R. L. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol. Endocrinol. 11, 54-66 (1997
164. Klijn, J. G., Setyono-Han, B., & Foekens, J. A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65, 825-830 (2000
165. Bakker, G. H., et al. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat. Rep. 71, 1021-1027 (1987
166. Michna, H., Schneider, M. R., Nishino, Y., & el Etreby, M. F. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res. Treat. 14, 275-288 (1989
167. Bakker, G. H., et al. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 37, 789-794 (1990
168. Iwasaki, K., et al. Effects of antiprogestins on the rate of proliferation of breast cancer cells. Mol. Cell. Biochem. 198, 141-149 (1999
169. Perrault, D., et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 14, 2709-2712 (1996
170. Jonat, W., et al. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann. Oncol. 24, 2543-2548 (2013
171. Robertson, J. F., Willsher, P. C., Winterbottom, L., Blamey, R. W., & Thorpe, S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35, 214-218 (1999